This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Template:SubstanceBox/Psilocybin mushrooms: Difference between revisions
Jump to navigation
Jump to search
>Isaak Make plus symbol consistent with other pages |
>Isaak Update durations based on study (citation added) |
||
| Line 78: | Line 78: | ||
|OralROA_TimelineFile= | |OralROA_TimelineFile= | ||
|OralROA_TimelineWidth= | |OralROA_TimelineWidth= | ||
|OralROA_Duration=[[Oral min total time:: | |OralROA_Duration=[[Oral min total time::6]] - [[Oral max total time::8]] [[Oral total time units::hours]] | ||
|OralROA_Onset=[[Oral min onset time:: | |OralROA_Onset=[[Oral min onset time::40]] - [[Oral max onset time::60]] [[Oral onset time units::minutes]] | ||
|OralROA_Comeup=[[Oral min comeup time:: | |OralROA_Comeup=[[Oral min comeup time::50]] - [[Oral max comeup time::70]] [[Oral comeup time units::minutes]] | ||
|OralROA_Peak=[[Oral min peak time:: | |OralROA_Peak=[[Oral min peak time::1.5]] - [[Oral max peak time::2]] [[Oral peak time units::hours]] <ref>{{cite journal | vauthors=((Pablo Mallaroni)), ((Natasha L. Mason )), ((Johannes T. Reckweg)), ((Riccardo Paci)), ((Sabrina Ritscher)), ((Stefan W. Toennes)), ((Eef L. Theunissen)), ((Kim P.C. Kuypers)), ((Johannes G. Ramaekers)) | journal=Clinical Pharmacology and Therapeutics | title=Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition | date= May 2023 | url=https://doi.org/10.1002/cpt.2958 | doi=10.1002/cpt.2958}}</ref> | ||
|OralROA_Offset=[[Oral min offset time:: | |OralROA_Offset=[[Oral min offset time::3]] - [[Oral max offset time::4]] [[Oral offset time units::hours]] | ||
|OralROA_Aftereffects=[[Oral min afterglow time::4]] - [[Oral max afterglow time::24]] [[Oral afterglow time units::hours]] | |OralROA_Aftereffects=[[Oral min afterglow time::4]] - [[Oral max afterglow time::24]] [[Oral afterglow time units::hours]] | ||
}} | }} | ||
Revision as of 15:07, 2 August 2023
| SubstanceBox/Psilocybin mushrooms | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||||||
| Common names | Psilocybin, Psilocybin mushrooms, Magic Mushrooms, Shrooms, 4-PO-DMT | ||||||||||||||||||||||||||||||||
| Substitutive name | 4-Phosphoryloxy-N,N-dimethyltryptamine | ||||||||||||||||||||||||||||||||
| Systematic name | 3-[2-(Dimethylamino)ethyl]-1H-indol-4-ol | ||||||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||||||
| Psychoactive class | Psychedelic | ||||||||||||||||||||||||||||||||
| Chemical class | Tryptamine | ||||||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
- ↑ Pablo Mallaroni, Natasha L. Mason , Johannes T. Reckweg, Riccardo Paci, Sabrina Ritscher, Stefan W. Toennes, Eef L. Theunissen, Kim P.C. Kuypers, Johannes G. Ramaekers (May 2023). "Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition". Clinical Pharmacology and Therapeutics. doi:10.1002/cpt.2958.